Orega Biotech Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Orega Biotech General Information

Description

Developer of monoclonal antibodies designed to transform scientific insights in the field of tumor immunology into improved responses to cancer immunotherapies. The company's antibodies deal with therapeutic strategies for cancer, focus on the tumor microenvironment and also develop antibodies for modulating regulatory cell activities in cancers, enabling researchers to facilitate improved anticancer strategies, response rates, and patient survival.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Espace Européen, Bâtiment G
  • 15 Chemin Du Saquin
  • 69130 Ecully
  • France
+33 04
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Espace Européen, Bâtiment G
  • 15 Chemin Du Saquin
  • 69130 Ecully
  • France
+33 04

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orega Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Dec-2022 Completed Clinical Trials - Phase 2
3. Early Stage VC 13-May-2014 Completed Clinical Trials - Phase 2
2. Early Stage VC 01-Sep-2010 $3.7M $3.7M Completed Startup
1. Accelerator/Incubator 01-Mar-2010 Completed Startup
To view Orega Biotech’s complete valuation and funding history, request access »

Orega Biotech Patents

Orega Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4110810-A1 Combination therapies based on ctla4 and il-17b inhibitors Pending 28-Feb-2020
US-20230045494-A1 Combination therapies based on ctla4 and il-17b inhibitors Pending 28-Feb-2020
WO-2021170750-A1 Combination therapies based on ctla4 and il-17b inhibitors Inactive 28-Feb-2020
EP-4007775-A1 Novel il-17b antibodies Pending 02-Aug-2019
US-20220281967-A1 Novel il-17b antibodies Inactive 02-Aug-2019 C07K16/244
To view Orega Biotech’s complete patent history, request access »

Orega Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orega Biotech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Turenne Groupe PE/Buyout Minority
UI Investissement PE/Buyout Minority
To view Orega Biotech’s complete investors history, request access »

Orega Biotech FAQs

  • When was Orega Biotech founded?

    Orega Biotech was founded in 2010.

  • Where is Orega Biotech headquartered?

    Orega Biotech is headquartered in Ecully, France.

  • What is the size of Orega Biotech?

    Orega Biotech has 7 total employees.

  • What industry is Orega Biotech in?

    Orega Biotech’s primary industry is Drug Discovery.

  • Is Orega Biotech a private or public company?

    Orega Biotech is a Private company.

  • What is Orega Biotech’s current revenue?

    The current revenue for Orega Biotech is .

  • How much funding has Orega Biotech raised over time?

    Orega Biotech has raised $5.08M.

  • Who are Orega Biotech’s investors?

    Turenne Groupe and UI Investissement have invested in Orega Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process